Theradaptive, Inc.

Theradaptive is a clinical-stage biotechnology company pioneering targeted protein therapeutics for tissue regeneration. The company leverages a proprietary protein engineering platform that converts recombinant proteins into material-binding variants, allowing for the precise, localized delivery of biologics to implants, devices, and injectable carriers. This technology aims to improve efficacy and reduce off-target effects in various clinical indications. The company's focus spans multiple therapeutic areas, including spine, orthopedics, dental, and soft tissue repair, with ongoing research into targeted immuno-oncology applications. Theradaptive is a venture-backed organization that has received significant support from the U.S. Department of Defense and other institutional investors to advance its pipeline toward commercialization.